Congress bans hidden kickbacks that inflate your pharmacy costs

What it does

This bill amends federal pension law (ERISA) to ban pharmacy benefit managers (PBMs) from paying kickbacks to brokers, consultants, or other intermediaries in exchange for steering business to them or influencing contract decisions. It closes loopholes by focusing on the economic substance of payments rather than their label, and presumes payments to intermediaries are kickbacks unless the parties prove otherwise with written documentation that the payment reflects fair market value for legitimate services.

Why we flagged it

The bill's operative mechanism is a direct prohibition on a specific form of compensation (kickbacks) paid by a named service provider (PBMs) to intermediaries. It is a narrow, targeted enforcement measure within existing ERISA fiduciary law, not a broad regulatory overhaul.

What the text implies

• Presumption that intermediary payments are kickbacks unless proven otherwise shifts burden of proof to PBMs and brokers, potentially reducing frivolous or borderline arrangements without explicit litigation.
• Focus on 'economic substance' over contractual labeling may catch arrangements structured to evade the prohibition by disguising kickbacks as consulting fees, market research, or other services.
• Effective date (plan years after enactment) gives PBMs and brokers time to restructure existing arrangements, but may create a transition period of uncertainty and renegotiation.
• Does not address other PBM revenue streams (spread pricing, formulary steering, rebate retention) — this is a narrow fix targeting one kickback channel, not comprehensive PBM reform.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary workers and retirees benefit by reducing hidden conflicts of interest in pharmacy benefit management. PBMs currently use kickbacks to intermediaries to secure contracts, inflating costs passed to plans and beneficiaries. Banning these payments removes a financial incentive for brokers and consultants to recommend PBMs based on kickback size rather than plan value, lowering total compensation costs and improving transparency in contracting.

Who stands to gain

• ERISA plan sponsors (employers, unions)
• Plan beneficiaries (workers, retirees)
• Pharmacy networks (reduced PBM leverage)

Named in the bill

Pharmacy Benefit Managers (PBMs), ERISA (Employee Retirement Income Security Act of 1974), Section 408(b)(2)(B), Brokers, consultants, advisors, Covered plans, Health insurance issuers

Where it stands

• Mar 12, 2026 — Introduced · Congress.gov: “Introduced in House”
• Mar 12, 2026 — Referred to House Committee on Education and Workforce · Congress.gov: “Referred to the House Committee on Education and Workforce”
• May 21, 2026 — Markup held in committee · Congress.gov: “Committee Consideration and Mark-up Session Held”
• May 21, 2026 — Reported out of committee · Congress.gov: “Ordered to be Reported (Amended) by the Yeas and Nays: 34 - 0”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

13 lobbying clients named this bill on 14 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $7,063,337 in lobbying spend. A filing names 16 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 94% of bills with at least one filing.

Rick Allen, the sponsor, reported $565,250 in PAC receipts in the 2026 cycle.

• Pharmaceutical Care Management Association — $3,282,990 on 1 filing
• Cambia Health Solutions — $700,000 on 1 filing
• Blood Cancer United (fka the Leukemia & Lymphoma Society) — $590,000 on 1 filing
• Food Marketplace Inc — $584,000 on 1 filing
• Council of Insurance Agents and Brokers — $350,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.